Spinocerebellar ataxia type 1 is caused by expansion of a translated CAG repeat in ataxin1 (ATXN1). The level of the polyglutamine-expanded protein is one of the factors that contributes to disease severity. Here we found that miR-19, miR-101 and miR-130 co-regulate ataxin1 levels and that their inhibition enhanced the cytotoxicity of polyglutamine-expanded ATXN1 in human cells. We provide a new candidate mechanism for modulating the pathogenesis of neurodegenerative diseases sensitive to protein dosage.
Polyglutamine (polyQ) diseases are dominantly inherited, neurodegenerative disorders that are caused by an expansion of CAG repeats that encode polyQ in the disease-causing protein [1] [2] [3] . In all of these disorders, the polyQ-expanded proteins are toxic, leading to the degeneration of specific neurons. Although animal studies have shown that the levels of the mutant protein contribute to polyQ disease severity [4] [5] [6] [7] , the in vivo mechanisms that regulate protein levels remain unknown.
To verify that mutant protein levels contribute to disease severity in the context of SCA1, we evaluated mice that overexpress SCA1 (ATXN1) with 82 CAG repeats under the control of the Purkinje cell-specific Pcp2 promoter (SCA1[82Q]) 4 Fig. 1 online) . These data suggest that increased amounts of mutant protein result in a more severe disease.
Human ATXN1 has a long 3¢ UTR (B7 kb), indicating that it might contain regulatory elements for post-transcriptional regulation (Fig. 1) . One mechanism for regulating the amount of gene expression involves microRNAs (miRNAs), endogenous small noncoding RNAs that bind the 3¢ UTR of cognate target mRNAs to suppress their expression 8 . Notably, impairment of miRNA biogenesis in Purkinje cells results in cerebellar degeneration and ataxia in mice 9 . Thus, we hypothesized that miRNA-mediated post-transcriptional regulation of ATXN1 might modulate SCA1 neuropathology by affecting the amount of the protein expressed.
To test this hypothesis, we searched for evolutionarily conserved miRNA-binding sites in the 3¢ UTR of human ATXN1 using miRNA target-prediction databases 10, 11 . Of the predicted miRNAs, we chose eight different miRNA candidates on the basis of the number of ATXN1 target sites and their neuronal expression. To validate the role of the selected miRNAs in modulating ATXN1 levels, we transfected MCF7 cells, which highly express endogenous ATXN1 ( Supplementary Fig. 2 online), with each miRNA duplex. miR-19a, miR-101 and miR-130a downregulated ATXN1 ( Supplementary  Fig. 2 ). Generally, different miRNAs act cooperatively on the same target mRNA to suppress its translation 8 . To determine whether this is the case for the miRNAs that we identified, we transfected different human cell lines (HEK293T, HeLa and MCF7 cells) with either each individual miRNA (miR-19a, miR-101 and miR-130a) or all of them combined. We observed a marked decrease in ATXN1 levels on cotransfection of all three miRNAs; transfection of 120 pmol of each miRNA individually also decreased ATXN1 levels (Fig. 1a,b and Supplementary Fig. 3 online). When we used 40 pmol of each individual miRNA, the reduction in ATXN1 levels was less pronounced in comparison with 40 pmol of all three combined ( Supplementary Fig. 3 ). Collectively, these data suggest that miR-19a, miR-101 and miR-130a cooperatively regulate ATXN1 levels. Notably, only miR-101 affected both mRNA and protein levels, whereas miR-19a and miR-130a reduced the amount of protein without changing the amount of mRNA in HeLa cells ( Supplementary Fig. 3 ). This suggests that miR-101 induces mRNA degradation as well as translational repression, whereas the others act primarily on translation. We also found that mouse ATXN1 is cooperatively regulated by these three miRNAs ( Supplementary Fig. 4 online) , suggesting that the mechanism of ATXN1 regulation by miR-19, miR-101 and miR-130 is conserved in mammals. When we used 2¢-O-methyl inhibitors against miR-19, miR-101 and miR-130a, we found that ATXN1 levels increased in HEK293T cells (Fig. 1c,d ). 
B R I E F C O M M U N I C AT I O N S
To confirm that miR-19, miR-101 and miR-130 directly target the 3¢ UTR of ATXN1, we linked firefly luciferase reporter genes to partial or full-length human ATXN1 3¢ UTR ( Supplementary Fig. 5 ) and carried out dual luciferase assays in HeLa cells. In the context of the fulllength 3¢ UTR (pGL3-hATXN1 3¢ UTR 1-7,015), miR-101 markedly reduced reporter gene expression, whereas we observed only a marginal reduction with miR-19a and miR-130a, as compared with the pGL3 control (Fig. 1e) . We observed marked suppression of two additional reporters containing the partial ATXN1 3¢ UTR in which miRNA target sites are enriched (pGL3-hATXN1 3¢ UTR 1-1,600 and 4,200-7,015) , with a clear correlation between the number of putative target sites and the degree of downregulation (Fig. 1e) . We then proceeded to identify the authentic miRNA target sites by mutagenizing each putative miRNA target site (except for the first miR-130 target site) conserved in vertebrates, as well as one miR-130 target site that is unique to humans (Supplementary Methods and Supplementary Figs. 6 and 7 online) . Most of the conserved putative miRNA target sites, except for the fourth miR-19 target site and the miR-130 target site unique to humans, were authentic ( Fig. 1f and Supplementary Figs. 6 and 7) . Together, these data indicate that miR-19, miR-101 and miR-130 directly bind to the ATXN1 3¢ UTR to suppress the translation of ATXN1.
Cerebellar Purkinje cells are vulnerable in individuals with SCA1 and animal models where mutant ATXN1 accumulates gradually and causes toxicity 4, 12, 13 . To examine the possibility that the level of ATXN1 could be regulated by miR-19, miR-101 and miR-130 in Purkinje cells, we investigated the expression pattern and level of these miRNAs in mouse cerebellum. Northern blot analysis demonstrated that they were expressed in the cerebellum ( Supplementary  Fig. 8 online) and RNA in situ hybridization revealed that miR-19b, miR-101 and miR-130 were expressed in Purkinje cells (Fig. 2) . Of note, however, miR-101 and miR-130 were more abundant than miR-19 in Purkinje cells (Fig. 2) , suggesting that miR-101 and miR-130 could dominantly act on ATXN1 in this brain region. Altogether, the expression of these miRNAs in the cells most vulnerable in this disease suggests that they could be involved in modulating the toxicity of mutant ATXN1.
To investigate whether these miRNAs modulate the cytotoxicity of the polyQ-expanded ATXN1, we generated a polyQ-expanded ATXN1 expression vector containing the wild-type 3¢ UTR of human ATXN1 (F86Q-3UTR WT) and carried out a cell-based assay of mutant ATXN1 toxicity (Supplementary Methods). We used HEK293T cells because the polyQ-expanded ATXN1 induces cell death in this cell line 14 and, more importantly, because molecular mechanisms that contribute to SCA1 pathogenesis in the cerebellum have been reproduced in this cell line in terms of the formation of the toxic protein complex containing the polyQ-expanded ATXN1 and RBM17 (ref. 15) . We tested whether inhibition of endogenous miR-19, miR-101 and miR-130 enhanced cytotoxicity of the polyQ-expanded ATXN1 (hATXN1[86Q]) expressed from F86Q-3UTR WT. Inhibition of these three miRNAs increased hATXN1[86Q] levels (Fig. 3a-c) . As a consequence, increased hATXN1[86Q] significantly reduced cell viability 48 and 72 h after transfection, in comparison with cotransfected F86Q-3UTR WT and control 2¢-O-methyl inhibitor (P o 0.01), although a mixture of inhibitors specific for each miRNA (miR-19a, miR-19b, miR-101 and miR-130b) also induced slightly more cell death than the control inhibitor (Fig. 3d) . To exclude the possibility that upregulation of other targets caused by inhibition of these miRNAs could contribute to a reduction in cell viability, we generated a hATXN1[86Q] expression vector containing the 3¢ UTR with mutated miRNA target sites (F86Q-3UTR Mut): three sites corresponding to miR-19 and a site corresponding to either miR-101 or miR-130 (Fig. 3a) . Mutation of these particular miRNA target sites not only increased the level of hATXN1[86Q] but also reduced cell viability (Fig. 3e-g ). These data suggest that the inhibition of miRNA-mediated post-transcriptional regulation of mutant ATXN1 enhances its cytotoxicity.
In this study, we provide evidence for a previously unknown key regulatory mechanism by discovering miRNAs that regulate the level of a polyQ disease causing protein in mammals and demonstrate the modulatory role of miRNA-mediated mechanisms in ATXN1 toxicity. The identification of this new modulatory pathway of ATXN1 begs the question of whether similar regulatory mechanisms exist for other polyQ proteins and for proteins implicated in neurodegenerative diseases that are caused by a gain-of-function mechanism and are sensitive to disease protein levels. Moreover, such findings raise the possibility that mutations in the miRNA-binding sites or the miRNA genes themselves might cause neurodegenerative phenotypes owing to an accumulation of ATXN1.
Note: Supplementary information is available on the Nature Neuroscience website.
